Alloy Therapeutics is a biotechnology company that democratizes access to foundational biologics discovery services and cutting-edge technology platforms. They offer a range of services including antibody discovery, TCR discovery, and genetic medicine, focusing on collaboration with academic scientists, small and medium biotech firms, and large biopharma companies. Their unique business model reinvests 100% of revenue into innovation, allowing them to continuously develop new technologies and maintain a strong market position. With a team of over 100 people across multiple research sites, Alloy Therapeutics is well-positioned to support drug discovery efforts and empower new drug companies through their venture studio.

Arzeda is a leading protein design company that leverages Intelligent Protein Design Technology™ to create novel proteins and enzymes for various industries, including food production, personal care, and sustainable materials. By combining physics-based design and AI, Arzeda develops innovative solutions that address real-world challenges, enhancing product performance and sustainability. The company collaborates with major industry players to optimize existing proteins and create entirely new ones, positioning itself as a key player in the protein design market with significant traction and impact.

Atomwise is a technology-enabled pharmaceutical company leveraging AI to revolutionize small molecule drug discovery. They have developed a best-in-class AI discovery engine that utilizes deep learning for structure-based drug design, enabling the identification and optimization of novel chemical compounds. Atomwise has validated its technology across various protein types and challenging drug targets, advancing a proprietary pipeline of small-molecule drug candidates. Their approach focuses on transforming drug discovery processes to invent better medicines for patients, positioning them as a leader in the AI-driven pharmaceutical landscape.

Benchling is a cloud-based platform designed for biotech R&D, enabling scientists to digitize their labs, automate workflows, and enhance productivity through AI. The platform supports a wide range of scientific data modeling and tracking, facilitating collaboration across various research domains such as bioresearch, bioprocess, and in vivo studies. With over 200,000 scientists using Benchling, including more than half of the world's top 50 biopharma companies, it has proven to significantly reduce time spent on data capture and increase research throughput. Benchling differentiates itself with its user-friendly interface, open platform for integrations, and a strong focus on customer success, making it a leading choice in the biotech industry.

BenchSci is a pioneering company that leverages advanced AI technology to enhance drug discovery processes. Their flagship product, ASCEND, is a generative AI platform designed to assist pharmaceutical R&D by providing a comprehensive understanding of disease biology. This platform integrates a vast biomedical dataset and employs multimodal AI to support complex research workflows, making it a scalable solution for preclinical organizations. With a strong focus on scientific explainability and a dedicated team of over 100 scientists and engineers, BenchSci aims to significantly improve the speed and quality of life-saving research and development, positioning itself as a leader in the biotech industry.

Bio Tissue is a pioneering company in regenerative medicine, utilizing human birth tissue to create innovative products that promote healing in ocular and surgical applications. Their proprietary Cryo Tek® technology preserves the structural integrity of tissues, enhancing their effectiveness in treating wounds and chronic pain. With over 900,000 human clinical applications and more than 400 peer-reviewed publications, Bio Tissue has established itself as a leader in the field, committed to ethical practices and high-quality standards. Their products, such as Prokera and Neox, are designed to help patients recover faster and achieve optimal healing outcomes, making them a trusted partner for healthcare professionals.

Biofourmis is a biotechnology company that leverages connected technology to revolutionize care delivery and drug development. By partnering with health systems and pharmaceutical companies, Biofourmis provides innovative solutions that enhance patient engagement, optimize medication management, and streamline clinical trials. Their platform enables life science companies to conduct digital clinical trials and commercialize therapies effectively, addressing critical challenges in healthcare. With a focus on improving clinical, operational, and economic outcomes, Biofourmis serves over 100,000 patients across various therapeutic areas, positioning itself as a leader in the healthcare technology space.

Biognosys is a leading provider of next-generation proteomics solutions, specializing in contract research services for the pharmaceutical and biotech industries. Their innovative technology enables precise quantification of large proteomes, facilitating biomarker discovery and drug-target validation. With a strong focus on quality, scale, and speed, Biognosys supports R&D and clinical trials, positioning itself as a key player in the life sciences market. The company has established a reputation for delivering actionable insights that improve human health, backed by a team of experts and a robust network of collaborators.

Boundless Bio is a clinical stage, next-generation precision oncology company focused on developing ec DNA-directed therapies for patients with oncogene amplified cancers. With a robust pipeline of innovative cancer medicines, the company aims to exploit the unique vulnerabilities of extrachromosomal DNA found in cancer cells, which affects over 14% of cancer patients. As a leader in this emerging field, Boundless Bio is dedicated to addressing the significant unmet medical need for effective treatments in this patient population, positioning itself as a pioneering force in oncology.

Carmot Therapeutics, now a member of the Roche Group, focuses on drug discovery and development aimed at improving clinical outcomes for individuals with metabolic diseases, particularly obesity and diabetes. Their innovative approach includes chemotype evolution and incretin receptor signaling bias, which differentiates them in the market. The acquisition by Roche enhances their scale and traction, positioning them strongly within the pharmaceutical industry.

CARsgen Therapeutics is a biopharmaceutical company focused on innovative CAR T-cell therapies for treating hematological malignancies and solid tumors. With operations in China and the U.S., the company aims to become a global leader in cell therapies, offering differentiated products like THANK-u CAR®, Cyclo CAR®, and LADAR®. Their integrated cell therapy platform and innovative pipeline position them strongly in the market, with recent FDA clinical holds lifted and ongoing pivotal trials demonstrating their commitment to making cancer curable.

Complete Genomics offers a range of end-to-end NGS solutions for spatial transcriptomics, utilizing proprietary DNBSEQ™ technology for accurate, cost-effective, and efficient sequencing. Their comprehensive solutions span from sample extraction to sequencing and analysis, enabling researchers to gain insights into genomic data with minimal oversight. The company aims to improve genomic accessibility and deliver cost-effective genomics, positioning itself as a leader in the field with innovative products and a disruptive market approach.